ストックスクリーナーアプリを入手
11.93
3.32%
-0.41
前日終値:
$12.34
開ける：
$12.48
24時間の取引高:
275.70K
Relative Volume:
0.64
時価総額：
$617.72M
収益：
-
当期純損益:
$-156.39M
株価収益率:
-3.2331
EPS:
-3.69
ネットキャッシュフロー:
$-123.06M
1週間 パフォーマンス:
+0.34%
1か月 パフォーマンス:
+11.60%
6か月 パフォーマンス:
-3.32%
1年 パフォーマンス:
+0.59%
1日の値動き範囲:
$11.82
$12.50
1週間の範囲:
$11.82
$12.58
52週間の値動き範囲:
$7.30
$15.50
Kalvista Pharmaceuticals Inc Stock (KALV) Company Profile
名前
Kalvista Pharmaceuticals Inc
セクター
電話
(857) 999-0075
住所
55 CAMBRIDGE PARKWAY, CAMBRIDGE, MA
KALV を他の銘柄と比較する
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
KALV
Kalvista Pharmaceuticals Inc
|
11.93 | 617.72M | 0 | -156.39M | -123.06M | -3.69 |
|
VRTX
Vertex Pharmaceuticals Inc
|
492.69 | 131.41B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
637.36 | 72.26B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
589.15 | 35.93B | 2.19B | 833.04M | -1.28B | 12.71 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
268.46 | 34.75B | 2.25B | -278.16M | -42.59M | -2.17 |
|
ONC
Beigene Ltd Adr
|
267.39 | 28.24B | 3.81B | -644.79M | -669.77M | -6.24 |
Kalvista Pharmaceuticals Inc Stock (KALV) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2025-01-31 | 開始されました | JMP Securities | Mkt Outperform |
| 2025-01-07 | 開始されました | TD Cowen | Buy |
| 2024-12-18 | 開始されました | BofA Securities | Buy |
| 2020-06-15 | 開始されました | H.C. Wainwright | Buy |
| 2019-07-29 | 開始されました | SVB Leerink | Outperform |
| 2019-03-20 | 開始されました | Needham | Buy |
| 2018-10-30 | 開始されました | Jefferies | Buy |
| 2018-09-21 | 開始されました | Cantor Fitzgerald | Overweight |
| 2017-08-31 | 開始されました | BTIG Research | Buy |
すべてを表示
Kalvista Pharmaceuticals Inc (KALV) 最新ニュース
KONFIDENT-KID trial of sebetralstat is now fully enrolled - Angioedema News Today
Cantor Fitzgerald maintains Overweight on Kalvista shares By Investing.com - Investing.com Australia
KalVista Pharmaceuticals enrols all subjects in hereditary angioedema drug trial - Yahoo Finance
Stifel maintains Buy on Kalvista stock, price target steady at $39 By Investing.com - Investing.com South Africa
Stifel maintains Buy on Kalvista stock, price target steady at $39 - Investing.com Australia
Cantor Fitzgerald maintains Overweight on Kalvista shares - Investing.com India
Kalvista stock holds as JMP reiterates $19 target By Investing.com - Investing.com Australia
KalVista Pharmaceuticals, Inc. (NASDAQ:KALV) Shares Sold by Bank of New York Mellon Corp - Defense World
Kalvista stock holds as JMP reiterates $19 target - Investing.com India
KalVista completes enrollment for pediatric HAE trial By Investing.com - Investing.com South Africa
KalVista Pharmaceuticals Completes Participant Enrollment Ahead of Schedule for Pediatric Hereditary Angioedema Trial - Marketscreener.com
KalVista completes enrollment for pediatric HAE trial - Investing.com India
KalVista Pharmaceuticals Announces Early Completion of Enrollment in KONFIDENT-KID Pediatric HAE Trial - Marketscreener.com
Breakthrough Pediatric HAE Drug Trial Hits Major Milestone: Patient Demand Surges 50% - StockTitan
KalVista Pharmaceuticals, Inc. (NASDAQ:KALV) Receives $23.80 Average Target Price from Analysts - Defense World
(KALV) Technical Pivots with Risk Controls - Stock Traders Daily
H.C. Wainwright maintains Buy on Kalvista, $20 target By Investing.com - Investing.com Canada
KalVista Pharmaceuticals’ (KALV) Buy Rating Reiterated at HC Wainwright - Armenian Reporter
H.C. Wainwright maintains Buy on Kalvista, $20 target - Investing.com India
KalVista Pharmaceuticals Stock (KALV): Advancements in HAE Treatment and Regulatory Progress - Value the Markets
HC Wainwright Reaffirms Buy Rating for KalVista Pharmaceuticals (NASDAQ:KALV) - Defense World
Needham & Company LLC Reiterates “Buy” Rating for KalVista Pharmaceuticals (NASDAQ:KALV) - Defense World
Buy Rating for KalVista Pharmaceuticals Driven by Anticipated FDA Approval and Strong Market Position - TipRanks
Sebetralstat provides early, fast relief for HAE attacks: Data - Angioedema News Today
Jefferies cuts Kalvista stock price target to $31 from $33 - Investing.com
Jefferies cuts Kalvista stock price target to $31 from $33 By Investing.com - Investing.com Canada
KalVista Pharmaceuticals Advances Sebetralstat for HAE - TipRanks
KalVista Pharmaceuticals, Inc. SEC 10-Q Report - TradingView
Kalvista Pharmaceuticals Inc reports results for the quarter ended January 31Earnings Summary - TradingView
KALVISTA PHARMACEUTICALS Earnings Results: $KALV Reports Quarterly Earnings - Nasdaq
KalVista Pharmaceuticals Reports Third Fiscal Quarter Results and Provides Operational Update - Business Wire
Reviewing KalVista Pharmaceuticals (NASDAQ:KALV) and Hillstream BioPharma (NASDAQ:HILS) - Defense World
KalVista Pharmaceuticals CEO sells $79,827 in stock By Investing.com - Investing.com Australia
KalVista Pharmaceuticals CEO sells $79,827 in stock - Investing.com
KalVista Pharmaceuticals CEO Sells Shares to Cover Tax Obligations - TradingView
KalVista Pharmaceuticals to Host Investor Webcast Highlighting Commercialization Strategy, Plans and Progress for Sebetralstat in Hereditary Angioedema - The Bakersfield Californian
Kalvista Pharmaceuticals Inc expected to post a loss of 87 cents a shareEarnings Preview - TradingView
JMP Securities sets $19 target for Kalvista Pharmaceuticals stock - MSN
JMP reiterates Kalvista stock with $19 target, sees market growth - MSN
KalVista Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Joplin Globe
KalVista Pharmaceuticals Shares Latest Sebetralstat Findings at the American Academy of Allergy, Asthma & Immunology 2025 Annual Meeting - BioSpace
Sebetralstat shows promise in treating HAE attacks By Investing.com - Investing.com Canada
Sebetralstat shows promise in treating HAE attacks - Investing.com India
KalVista stock holds firm with $19 target from JMP - Investing.com India
KalVista stock holds firm with $19 target from JMP By Investing.com - Investing.com South Africa
Kalvista Pharmaceuticals Inc (KALV) 財務データ
収益
当期純利益
現金流量
EPS
Kalvista Pharmaceuticals Inc (KALV) インサイダートレーディング
| インサイダートレーディング | 関係 | 日付 | 取引 | コスト | #株式 | 値 ($) | #株式総数 |
|---|---|---|---|---|---|---|---|
| Audhya Paul K. | CHIEF MEDICAL OFFICER |
Feb 24 '25 |
Sale |
10.02 |
2,394 |
23,988 |
102,940 |
| Yea Christopher | CHIEF DEVELOPMENT OFFICER |
Feb 24 '25 |
Sale |
10.02 |
1,918 |
19,218 |
93,952 |
| Yea Christopher | CHIEF DEVELOPMENT OFFICER |
Feb 18 '25 |
Sale |
9.82 |
2,601 |
25,553 |
92,745 |
| Audhya Paul K. | CHIEF MEDICAL OFFICER |
Feb 18 '25 |
Sale |
9.82 |
3,125 |
30,701 |
100,334 |
| Palleiko Benjamin L | CHIEF EXECUTIVE OFFICER |
Feb 18 '25 |
Sale |
9.82 |
5,104 |
50,143 |
278,855 |
| Venrock Healthcare Capital Par | 10% Owner |
Feb 12 '25 |
Buy |
9.23 |
100,000 |
923,000 |
5,217,285 |
| Venrock Healthcare Capital Par | 10% Owner |
Feb 13 '25 |
Buy |
9.33 |
61,700 |
575,661 |
5,278,985 |
| Venrock Healthcare Capital Par | 10% Owner |
Feb 07 '25 |
Buy |
9.29 |
73,649 |
684,199 |
5,086,445 |
| Venrock Healthcare Capital Par | 10% Owner |
Feb 11 '25 |
Buy |
9.18 |
26,703 |
245,134 |
5,117,285 |
| Venrock Healthcare Capital Par | 10% Owner |
Feb 10 '25 |
Buy |
9.14 |
4,137 |
37,812 |
5,090,582 |
0.39%
0.34%
大文字化:
|
ボリューム (24 時間):